Patents by Inventor Laurence C. Eisenlohr

Laurence C. Eisenlohr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11365174
    Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: June 21, 2022
    Assignees: Thomas Jefferson University, Ramot At Tel-Aviv University LTD.
    Inventors: Nir Ben-Tal, Roger S. Armen, Laurence C. Eisenlohr, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
  • Patent number: 10676428
    Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: June 9, 2020
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Nir Ben-Tal, Roger S. Armen, Laurence C. Eisenlohr, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
  • Publication number: 20180370910
    Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.
    Type: Application
    Filed: December 19, 2016
    Publication date: December 27, 2018
    Applicants: Thomas Jefferson University, Ramot at Tel-Aviv University Ltd.
    Inventors: Nir Ben-Tal, Roger S. Armen, Laurence C. Eisenlohr, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
  • Publication number: 20040214193
    Abstract: Recoding of the genetic code, through +1 frameshifting, −1 frameshifting or stop codon readthrough, will alter the protein that is translated from that gene. Current systems that quantify recoding events have limited sensitivity, and can only be used in cell extracts or tissue culture. A novel method for detecting a recoding event is described that uses the sensitivity and specificity of CD8+ T-cells for measuring recoding, both in vivo and in vitro. This enhanced sensitivity allows for the identification of compounds that are used to regulate recoding, and therefore protein translation.
    Type: Application
    Filed: July 28, 2003
    Publication date: October 28, 2004
    Applicants: Thomas Jefferson University, University of Utah Research Foundation
    Inventors: Laurence C. Eisenlohr, Michael T. Howard
  • Publication number: 20030086906
    Abstract: A method of inducing expression of immune active cytokines in tumors in situ is provided wherein a vaccinia virus vector capable of inducing expression of a selected cytokine is generated and injected into a tumor so that cells of the tumor express the selected cytokine. A method of enhancing immunity in a host by administration of a vaccinia virus vector is also provided. Methods of treating cancer by administration of these vaccinia virus vectors are also provided.
    Type: Application
    Filed: November 4, 2002
    Publication date: May 8, 2003
    Inventors: Michael J. Mastrangelo, Edmund C. Lattime, David Berd, Laurence C. Eisenlohr
  • Patent number: 6475999
    Abstract: A method of inducing expression of immune active cytokines in tumors in situ is provided wherein a vaccinia virus vector capable of inducing expression of a selected cytokine is generated and injected into a tumor so that cells of the tumor express the selected cytokine. A method of enhancing immunity in a host by administration of a vaccinia virus vector is also provided. Methods of treating cancer by administration of these vaccinia virus vectors are also provided.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: November 5, 2002
    Assignee: Thomas Jefferson University
    Inventors: Michael J. Mastrangelo, Edmund C. Lattime, David Berd, Laurence C. Eisenlohr
  • Publication number: 20020068274
    Abstract: Recoding of the genetic code, through +1 frameshifting, −1 frameshifting or stop codon readthrough, will alter the protein that is translated from that gene. Current systems that quantify recoding events have limited sensitivity, and can only be used in cell extracts or tissue culture. A novel method for detecting a recoding event is described that uses the sensitivity and specificity of CD8+ T-cells for measuring recoding, both in vivo and in vitro. This enhanced sensitivity allows for the identification of compounds that are used to regulate recoding, and therefore protein translation.
    Type: Application
    Filed: October 16, 2001
    Publication date: June 6, 2002
    Inventors: Laurence C. Eisenlohr, Michael T. Howard
  • Patent number: 6093700
    Abstract: A method of inducing expression of immune active cytokines in tumors in situ is provided wherein a vaccinia virus vector capable of inducing expression of a selected cytokine is generated and injected into a tumor so that cells of the tumor express the selected cytokine. A method of enhancing immunity in a host by administration of a vaccinia virus vector is also provided. Methods of treating cancer by administration of these vaccinia virus vectors are also provided.
    Type: Grant
    Filed: February 20, 1997
    Date of Patent: July 25, 2000
    Assignee: Thomas Jefferson University
    Inventors: Michael J. Mastrangelo, Edmund C. Lattime, David Berd, Laurence C. Eisenlohr